UAE femtech firm raises US$1.2m pre-seed funding

UAE-based femtech startup Ovasave has raised US$1.2m in early funding to expand its fertility and hormone health services across Saudi Arabia and the wider GCC.

The digital-first platform, founded in 2023 by Majd Abu Zant and Torkia Mahloul, offers at-home hormone testing, virtual consultations, personalised supplement protocols and egg freezing support.

The funding will support regional expansion, scale corporate partnerships and fund the next phase of the company’s mobile app. Planned features include menstrual tracking, symptom monitoring, access to care and AI-driven treatment protocols.

Majd Abu Zant, co-founder of Ovasave, said: “Abu Dhabi’s focus on innovation, healthcare, and entrepreneurship has created a competitive environment for founders and investors alike.

“As an Abu Dhabi-based startup supported by Hub71, Ovasave has benefited from a strong regulatory framework, access to capital, and proximity to regional decision-makers.

“It’s the right environment to build and scale high-impact ventures, and from here, we are expanding into Saudi Arabia and the wider MENA region.”

Ovasave combines fertility testing, hormone management, egg freezing coordination and menopause support in one platform.

It also partners with employers to offer reproductive health services as part of workplace wellbeing programmes.

The startup has collaborated with organisations including Aldar, Boston Consulting Group and WeWork to promote fertility awareness in the workplace.

It also ran a campaign with Merck Gulf offering free AMH (anti-Müllerian hormone) tests — which measure ovarian reserve — to over 500 women in the UAE.

Torkia Mahloul, co-founder and CEO of Ovasave, said: “There is a critical need for timely intervention in women’s health, particularly around fertility and hormonal health.

“This funding marks a crucial step in our mission to disrupt women’s health and expand access to fertility and hormonal care across the region.

“We are grateful for the confidence shown by our investors, which allows us to scale a platform designed to deliver timely, personalised, and accessible fertility and hormonal care.

“By bringing together medical expertise, digital convenience, and emotional support, we are helping women take control of their health earlier and more effectively across different life stages.”